as 09-17-2025 4:00pm EST
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Founded: | 2002 | Country: | United States |
Employees: | N/A | City: | PRINCETON |
Market Cap: | 2.5B | IPO Year: | 2007 |
Target Price: | $28.00 | AVG Volume (30 days): | 3.6M |
Analyst Decision: | Buy | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.12 | EPS Growth: | N/A |
52 Week Low/High: | $5.51 - $12.65 | Next Earning Date: | 11-05-2025 |
Revenue: | $571,160,000 | Revenue Growth: | 25.35% |
Revenue Growth (this year): | 20.98% | Revenue Growth (next year): | 20.74% |
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
MT Newswires
3 months ago
GlobeNewswire
3 months ago
Insider Monkey
3 months ago
Zacks
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
4 months ago
Simply Wall St.
4 months ago
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.